Poster Session A - Sunday Afternoon
Category: IBD
Kanwarpreet Tandon, MD
Cleveland Clinic Florida
Weston, FL
Variable | Responders (n=29) | Non-Responders (n=20) | P Value |
Age | 51.45 ± 13.05 | 52.42 ± 17.31 | 0.55 |
Gender (Female) | 51.7% | 63.2% | 0.43 |
Race Asian Black Caucasian Hispanic |
0 0 93.1% 6.9% |
5.3% 0 94.7% 0 |
0.82 |
Body Mass index | 28.99 ± 7.4 | 26.62 ± 4.93 | 0.23 |
Type of IBD Ulcerative Colitis Crohn’s disease |
65.5 % 34.5% |
84.2% 15.8% | 0.16
|
Type of biologic Anti-TNF Vedolizumab/Ustekinumab |
48.3% 51.7% |
78.9% 21.1% | 0.04
|
Initial lymphocyte count | 1.71 ± 0.61 | 1.56 ± 0.95 | 0.51 |
Initial Monocyte count | 0.66 ± 0.31 | 0.63 ± 0.30 | 0.75 |
Initial Neutrophil count | 5.51 ± 3.15 | 5.66 ± 2.00 | 0.85 |
Initial NLR | 3.64 ± 2.74 | 4.85 ± 2.91 | 0.16 |
Initial LMR | 2.86 ± 1.12 | 2.59 ± 1.22 | 0.43 |
Follow up lymphocyte count | 1.78 ± 0.58 | 1.58 ± 0.58 | 0.26 |
Follow up monocyte count | 0.58 ± 0.20 | 0.57 ± 0.32 | 0.85 |
Follow up Neutrophil count | 4.24 ± 1.31 | 4.47 ± 1.23 | 0.53 |
Follow up NLR | 2.70 ± 1.47 | 3.57 ± 2.68 | 0.17 |
Follow up LMR | 3.33 ± 1.32 | 3.39 ± 1.65 | 0.88 |
Duration of follow up | 52 weeks | 29.90 ± 12.53 weeks | 0.99 |
Steroid use | 58.6% | 57.9% | 0.96 |